sale project
versu
extens two year use adjuv
set prior model reflect metastat
prospect rhhbi increas
azn lower roughli unchang
azn
view adjuv expect
conserv azn lead earli
rhhbi studi
forecast sale comparison
last publish forecast increas due sever factor
rhhbi forecast increas azn lower posit roughli
model extend broaden reach
sinc last updat may model chang includ recent data
approv file withdraw kol feedback two new tumor type colorect
ovarian join previous model model extens
use adjuv set prior model metastat potenti adjuv
support posit trial data azn pacif phase trial
way nine tumor type despit big number view adjuv project
conserv
summari sale chang project compani
azn imfinzi durvalumab estim decreas
decreas metastat lung due mystic failur far decreas
metastat bladder increas adjuv lung due pacif
project imfinzi sale impli ww market share
opdivo nivolumab forecast increas forecast market
share increas tumor type metastat set new
indic increas head neck row approv
notabl decreas hepatocellular carcinoma european file withdraw
adjuv indic contribut adjuv gastric bladder
contribut project opdivo sale ww
market share
keytruda pembrolizumab project increas forecast
market share increas tumor type metastat set
new indic notabl decreas head neck given row approv
adjuv indic contribut adjuv bladder melanoma
gastric contribut project keytruda sale ww
market share
bavencio avelumab estim increas increas
metastat lung adjuv tnbc decreas metastat bladder
project bavencio sale ww market share
rhhbi tecentriq atezolizumab forecast increas five
potenti adjuv opportun roch appear well-posit sole pursuant
adjuv ovarian adjuv indic contribut
adjuv bladder tnbc contribut project tecentriq sale
ww market share
pleas see page report import disclosur
sale estim compani tumor type total annual sale report red
cowen compani
 model base tumor type main focu current metastat adjuv io studi melanoma renal cell carcinoma rcc lung cancer gastric cancer bladder cancer head neck cancer tripl neg
breast cancer tnbc classic hodgkin lymphoma chl merkel cell carcinoma mcc hepatocellular carcinoma colorect cancer ovarian cancer
updat model includ estim io therapi adjuv set target earlier stage diseas metastat set advanced/metastatic/relaps refractori case
larg variat potenti io patient rel annual incid tumor type reflect typic stage diagnosi late stage lung gastric earlier stage melanoma
price row us annual cost per patient base keytruda/opdivo monthli wac estim weight averag durat therapi tumor type metastat set page adjuv set page
row inclus country/region differ broken
treatment includ mono combo therapi
cowen compani
reflect modelastrazenecau metastat metastat adjuv lung bladder lung ww sale ww market melanoma gastric lung rcc bladder chl melanoma rcc lung bladder ww sale ww market melanoma lung bladder gastric chl tnbc merkel cell melanoma lung gastric bladder rcc tnbc ww sale ww market lung rcc merkel cell tnbc merkel cell ww sale ww market lung rcc bladder tnbc rcc bladder tnbc colorect ww sale ww market metastat adjuv sale row sale ww sale cowen
cowen compani
reflect modellung canceru metastat metastat adjuv azn azn lung rhhbi cell carcinoma rhhbi azn azn bladder gastric neck cancer metastat azn adjuv neg breast cancer rhhbi hodgkin lymphoma metastat adjuv cell carcinoma metastat adjuv carcinoma metastat adjuv cancer metastat rowm adjuv wwm ovarian metastat adjuv sale row sale chg cowen
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
estim market share compani head neck cancer hodgkin lymphoma metastat set
cowen compani
estim market share compani hepatocellular carcinoma merkel cell carcinoma mcc metastat set
cowen compani
cowen compani
cowen compani
cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale sale lung cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale sale ww sale cowen
cowen compani
cancershar adjuv market patient per cancer sale cell carcinoma rcc share adjuv market patient per sale sale lung cancershar adjuv market patient per cancer sale cell carcinoma rcc share adjuv market patient per sale sale ww sale cowen
cowen compani
cowen compani
market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale hodgkin lymphoma chl share market patient per sale carcinoma share market patient per sale cancershar market patient per cancer sale colorect mh-crc share market patient per sale sale market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale hodgkin lymphoma chl share market patient per sale cancershar market patient per cancer sale colorect mh-crc share market patient per sale sale ww sale cowen
cowen compani
market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale sale market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale sale ww sale cowen
cowen compani
cowen compani
market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancer share market patient per sale hodgkin lymphoma chl share market patient per sale neg breast cancer tnbc share market patient per sale carcinoma share market patient per sale cell carcinoma mcc share market patient per sale colorect cancer mh-crc share market patient per sale sale melanomashar market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale neck cancershar market patient per neck cancer sale hodgkin lymphoma chl share market patient per neg breast cancer tnbc share market patient per sale carcinoma share market patient per sale cell carcinoma mcc share market patient per sale colorect cancer mh-crc share market patient per sale row sale ww sale cowen
cowen compani
market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale neg breast cancer tnbc share market patient per sale sale melanomashar market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
cowen compani
 cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma mcc share market patient per sale sale renal cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale cell carcinoma mcc share market patient per sale row sale ww sale cowen
cowen compani
 neg breast cancer tnbc share market patient per sale sale tripl neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
cowen compani
market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale sale market patient per sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
colorect mh-crc share market patient per sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale sale colorect mh-crc share market patient per sale cancershar market patient per cancer sale cell carcinoma rcc share market patient per sale cancershar market patient per cancer sale neg breast cancer tnbc share market patient per sale row sale ww sale cowen
cowen compani
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
cancer pt newli annual new case growth growth rate pt lung cancer nsclc pt pt nsclc metastat local advanc diseas diagnosi total potenti lung i-o patient pt therapi pt mono combo therapi melanoma pt newli annual growth rate growth rate pt metastat diagnosi estim total potenti melanoma i-o pt therapi current therapi chemo/target therapi pt mono combo therapi renal cell carcinoma rcc pt newli annual growth rate growth rate pt estim rangetot potenti renal i-o patient pt therapi current therapi new agent futur pt mono combo therapi bladder cancer pt newli annual new case growth pt newli diagnos case advanc total potenti bladder i-o pt therapi pt mono combo therapi gastric cancer pt newli annual new case growth growth rate pt newli diagnos case stage iv total potenti gastric i-o patient pt therapi pt mono combo therapi head neck cancer pt newli annual new case growth pt squamou histolog pt pt advanc local advanc diseas diagnosi total potenti head neck i-o patient pt therapi pt mono combo therapi tripl neg breast cancer tnbc pt newli diagnos flat accord cdc pt metastat diseas breast cancer becom metastat pt metastat diseas pt tnbc metastat breast cancer tripl negativetot potenti tnbc i-o patient pt therapi pt hodgkin lymphoma chl pt newli diagnos flat accord nih pt relaps refractori diseas rate pt relaps refractori diseas pt therapi pt carcinoma pt newli estim flat annual incid pt advanc diseas locoregion diseas unresect pt unresect diseas pt therapi pt cell carcinoma mcc pt newli cancer societi estim case per year pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt colorect cancer pt newli newli diagnos accord cdc pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas tumor msi-h pt r/r diseas pt therapi pt total pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
row cancer pt newli annual growth assum preval tobacco use pt lung cancer nsclc pt pt nsclc metastat initi diagnosi total potenti lung i-o patient pt therapi geograph divers popul hinder penetr pt mono combo therapi melanoma pt newli annual new case growth pt present w/metastasestot potenti melanoma i-o market estimate size us pt therapi pt mono combo therapi renal cell carcinoma rcc pt newli annual growth assum preval tobacco use pt estim rangetot potenti renal i-o patient pt therapi pt mono combo therapi bladder cancer pt newli annual new case growth pt newli diagnos case advanc total potenti bladder i-o pt therapi pt mono combo therapi gastric cancer pt newli annual new case growth pt newli diagnos case stage iv total potenti gastric i-o patient preval emerg market pt therapi yr base penetr develop countri pt mono combo therapi head neck cancer pt newli annual new case growth pt squamou histolog pt pt advanc local advanc diseas diagnosi total potenti head neck i-o patient pt therapi pt i-o given high preval emerg market pt mono combo therapi tripl neg breast cancer tnbc pt newli diagnos flat assum cdc pt metastat diseas breast cancer becom pt metastat diseas pt tnbc metastat breast cancer tripl negativetot potenti tnbc i-o patient pt therapi pt hodgkin lymphoma chl pt newli cancer research estim annual ou incid pt relaps refractori diseas rate pt relaps refractori diseas pt therapi pt carcinoma pt newli estim annual ou incid pt advanc diseas locoregion diseas unresect pt relaps refractori diseas pt therapi pt cell carcinoma mcc pt newli incid pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt colorect cancer pt newli million new case world-wide pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas tumor msi-h pt r/r diseas pt therapi pt total pt mainten patient w/advanc diseaseestim total pt lung cancer cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
cancer pt newli annual new case growth growth rate pt lung cancer nsclc pt pt non-metastat stage local stage ii region stage early-stag resect without early-stag resect adjuv io potenti lung adjuv io patient pt therapi pt pt newli annual growth rate growth rate pt non-metastat stage present w/metastas project rest i- early-stag resect w/o early-stag resect adjuv io potenti melanoma adjuv io pt therapi current therapi chemo/target therapi pt cell carcinoma rcc pt newli annual growth rate growth rate pt non-metastat stage rcc present local region stage i- early-stag resect w/o early-stag io potenti renal adjuv io patient pt therapi pt cancer pt newli annual new case growth pt non-metastat stage newli case advanc early-stag resect w/o early-stag resect adjuv io potenti bladder adjuv io pt therapi pt cancer pt newli annual new case growth growth rate pt non-metastat stage gastric cancer stage early-stag resect w/o receiv neo/adj doc discret early-stag io potenti gastric adjuv io patient pt therapi pt neg breast cancer tnbc pt newli diagnos flat accord cdc pt pt pt non-metastat stage bc diagnos i- estim stage tabl early-stag resect w/o early-stag io potenti early-stag tnbc adjuv io pt therapi pt cancer pt newli newli diagnos accord cdc pt non-metastat stage local region stage i- diseas early-stag resect w/o i-ii discret stage io-eligbl early-stag io colon resect w/o adj resect w/ possibl adjtot potenti colorect adjuv io patient rectal resect io elig pt therapi pt cancer pt newli newli diagnos accord cdc pt non-metastat stage ovarian cancer diagnos stage i- early-stag resect w/o early-stag io potenti ovarian adjuv io patient pt therapi pt total pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
row cancer pt newli annual growth assum preval tobacco use pt lung cancer nsclc pt pt non-metastat stage local stage ii region stage nsclc early-stag resect w/o nsclc early-stag io potenti lung adjuv io patient pt therapi geograph divers popul hinder penetr pt pt newli annual new case growth pt present w/metastas project rest i- early-stag resect w/o elig io resect doc discret early-stag io potenti melanoma adjuv io market estimate slightli larger us base kol insight pt therapi pt cell carcinoma rcc pt newli annual growth assum preval tobacco use pt rcc present local region stage i- early-stag resect w/o early-stag io potenti renal adjuv io patient pt therapi pt cancer pt newli annual new case growth pt newli case advanc early-stag resect w/o early-stag io potenti bladder adjuv io pt therapi pt cancer pt newli annual new case growth growth rate pt gastric cancer diagnos stage row early-stag resect w/o early-stag io potenti gastric adjuv io patient pt therapi geograph divers popul hinder penetr pt neg breast cancer tnbc pt newli diagnos flat assum cdc pt breast cancer tripl neg pt pt non-metastat stage bc diagnos i- estim stage tabl early-stag resect w/o early-stag io potenti tnbc adjuv io patient pt therapi geograph divers popul hinder penetr pt cancer pt newli million new case world-wide pt non-metastat stage local region stage i- diseas early-stag resect w/o i-ii discret stage io-eligbl early-stag io colon resect w/o adj resect w/ possibl adjtot potenti colorect adjuv io patient rectal resect io elig pt therapi geograph divers popul hinder penetr pt cancer pt newli new case diagnos ww pt non-metastat stage ovarian cancer diagnos stage i- early-stag resect w/o early-stag io potenti ovarian adjuv io patient pt therapi pt total pt mainten patient early-stag diseaseestim total pt cowen
cowen compani durat therapi respond non respond estim cowen kol feedback
melanomalungrccbladd durat therapi respond durat non respond averag durat cost per cours cowen
cowen compani durat therapi respond non respond estim cowen kol feedback
lungmelanomarccbladd gastrictnbccrcovarianpati complet adjuv complet adjuv durat adjuv therapi durat failur averag durat cost per cours cowen
cowen compani
median mo overal mo local advanc phase phase nivo phase phase phase nivo mg mg mg mg mg mg mg phase pembro mg/kg mg/kg phase phase cohort cohort phase avelumab phase i- w/avastin phase atezo carb pac arm atezo carb pac bev arm arm phase ii atezo chemo brain brain phase ii atezo phase ii atezo phase atezo ib w/avastin /-chemo solid tumor atezo bev arm atezo bev folfox arm atezo carb pac arm arm arm phase atezo w/pt base chemo atezo pac carb cancer non-smal cell lung carcinoma nsclc month sourceorr cowen
cowen compani
yr mo mo nave phase nivo mg/kg phase phase ii nivo mg/kg mg/kg refractori phase nivo mg/kg choic chemo phase nivo mg/kg phase nivo mg/kg mg/kg mg/kg ph adjuv vs resect stage -iv melanoma nivo mg/kg mg/kg dose refractori phase refractori phase phase pembro ido phase braf melanoma data pool lancet sourc esmo cowen
cowen compani
renal phase iinivo phase phase nivo phase nivo mg/kg mg/kg ph ii w/bev vs phase ii avastin phase cancerazndurvalumab phase phase phase phase ii phase phase ii phase phase phase ii phase phase neg breast cancer phase phase ii phase phase abraxan abraxan abraxan abraxan cancermmr-defici nivo nivo msi-h avastin avastin avastin folfox canceraznphas nivo phase nivo phase japan phase nivo phase placebo phase nivo nivo nivo phase lancetkn solid tumor phase avelumab malign page type/companybmysourcemo mo orr month cowen
cowen compani
mo yr yr -mpf mo mo hodgkin phase phase ii phase phase ii hodgkin phase b-cell lymphoma larg b-cell i/iia nivo ibrutinibchron lymphocyt leukemia lymphocyticlymphoma larg b-cell cell lung cancer phase i/ii nivo phase i/ii nivo phase canceraznphas phase carcinomamrkpembro phase ib cell carcinomajavelin merkel ph neck -hpv hpv-monthsaznphas nivo phase chemo phase nivo liri phase phase phase phase durva treme durva ph durva mono ph malign page cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
